World’s First,
Global Pioneer in
Tiger Milk Mushroom Cultivation
From Malaysia’s rainforests, LiGNO Biotech pioneered the world’s first cultivation of the Tiger Milk Mushroom, transforming a centuries-old tradition into a clinically validated wellness solution.
LiGNO®
Functional Mushroom Ingredients
Scientifically Validated Bioactivities
Anti-inflammatory
Immunomodulating
Bronchodilating
Anti-asthmatic Activity
Anti-proliferative
Anti-viral
Improves Insulin Sensitivity
Antioxidant
Anti-glycation
Enhances ATP And Energy Production
Neurotrophic (Supports Nerve Growth)
Product Specifications
≥15% Glycoprotein
≥30% Total Polysaccharides
≥15% Beta Glucan
Applications
LiGNO TM02® is a versatile ingredient, perfect for a wide range of product categories, including:
Nutraceuticals
Functional Food & Beverage
Dietary Supplements
Skincare
Products
Pet Health
Products
Applications
LiGNO TM02® is a versatile ingredient, perfect for a wide range of product categories, including:
Nutraceuticals
Functional Food & Beverage
Dietary Supplements
Skincare Products
Pet Health Products
TM02®
Portfolio
LiGNO TM02® Skincare Extract
A standardized cold-water extract formulated for skincare applications.
Soothe irritated skin caused by allergies
Calm eczema-prone or sensitive skin
Promote overall skin wellness and resilience
SUMMARY OF CLINICAL TRIAL OF TIGER MILK MUSHROOM
1. Respiratory Health (Asthma Study)
A Phase II clinical study investigated TM02® as a complementary support for individuals with uncontrolled asthma.
Participants
17 adults with asthma
Duration
90 days
Dosage
600 mg → 1,200 mg daily
| Parameter | Direction | Number/Percentage | Description |
|---|---|---|---|
| Lung Function (FEV1) | Increase | +0.3 Liters (20.1%) | Demonstrates improved airway patency and significantly better lung capacity. |
| Airway Inflammation (FeNO) | Decrease | -21.2 ppb (43%) | Indicates a major reduction in allergic airway inflammation, which is a key driver of asthma symptoms. |
| Asthma Symptoms (ACQ-7) | Decrease | -0.8 units | A reduction in the "Asthma Control Questionnaire" score, meaning patients experienced significantly fewer symptoms and better quality of life. |
| Blood Eosinophils | Decrease | 48.7% | A drop in the specific white blood cells responsible for causing lung tissue damage and asthma attacks. |
| Serum IgE | Decrease | 22.1% | Lowered levels of Immunoglobulin E (IgE) antibodies, showing a reduction in the body's overactive allergic response |
Key Findings:
Significant improvement in lung function:
(FEV1 increased
↗ by 0.3 L)
Improved asthma control:
(reduced
↘ ACQ-7 scores by 0.8 points)
Reduced airway inflammation:
• FeNO reduced ↘ by 43%
• Lower ↘ eosinophil count and IgE levels
Conclusion:
TM02® may support respiratory health by improving breathing function and reducing inflammation.
2.
Cancer Recovery (Breast Cancer Study)
A randomized, double-blind, placebo-controlled trial evaluated TM02® in patients recovering from breast cancer treatment.
Participants
52 patients
Duration
6 months
Dosage
1,040 mg daily
| Parameter | Direction | Key Detail |
|---|---|---|
| Global Health Status (GHS) | Increase | There was a significant within-patient improvement in overall health and quality of life scores across the 6-month study. |
| Physical Functioning | Increase | A positive trend was observed in patients' ability to perform daily physical activities compared to the placebo group. |
| ATP (Energy) Production | Increase | Supplementation is linked to dramatically increased ATP production by improving mitochondrial function. |
| Fatigue Scores | Decrease | There was a noticeable decreasing trend in fatigue, with survivors in the TM02® group reporting lower tiredness levels than those on the placebo. |
Key Findings:
Quality of Life (Global Health Status):
Showed a significant within-patient improvement
↗ from a baseline of 68.13 to approximately 75.0 by the final visit.
Physical Functioning:
Improved
↗ from a baseline of 81.0 to approximately 89.5 by the end of the study.
Fatigue Score:
Observed a decreasing trend in fatigue scores compared to the placebo group.
Cellular Energy:
Supplementation was noted to dramatically increase ↗ ATP production by improving mitochondrial function.
Conclusion: TM02® may help improve overall well-being and reduce fatigue in post-treatment recovery.
3. Physical Fitness (Resistance Training Study)
A double-blind study evaluated TM02® in combination with resistance training.
Participants
40 healthy young males
Duration
8 weeks
Dosage
500 mg daily
I. Muscular Strength (Peak Torque at 60°/s in Nm)
These figures represent the maximum force generated by the muscles. Higher numbers indicate greater strength.
| Metric | RT (Exercise Only) | RT+TM02 (Combined) | TM02 Only (LRS) | Placebo (Control) |
|---|---|---|---|---|
| Shoulder Extension | Pre: 56.7 Post: 63.2 | Pre: 63.6 Post: 72.2 | Pre: 52.0 Post: 64.1 | Pre: 58.2 Post: 52.9 |
| Shoulder Flexion | Pre: 53.6 Post: 59.4 | Pre: 59.0 Post: 61.1 | Pre: 56.8 Post: 60.0 | Pre: 47.7 Post: 49.0 |
| Knee Extension | Pre: 143.3 Post: 166.1 | Pre: 173.4 Post: 187.0 | Pre: 149.5 Post: 152.5 | Pre: 138.0 Post: 141.7 |
| Knee Flexion | Pre: 62.2 Post: 75.0 | Pre: 77.8 Post: 90.0 | Pre: 63.8 Post: 72.6 | Pre: 64.1 Post: 69.9 |
II. Muscular Power (Average Power at 300°/s in Watts)
This measures the ability to exert force quickly. Higher numbers indicate more explosive power.
| Metric | RT (Exercise Only) | RT+TM02 (Combined) | TM02 Only (LRS) | Placebo (Control) |
|---|---|---|---|---|
| Shoulder Power (Ext) | Pre: 63.0 Post: 96.9 | Pre: 84.6 Post: 118.9 | Pre: 81.4 Post: 95.1 | Pre: 61.9 Post: 64.3 |
| Shoulder Power (Flex) | Pre: 75.7 Post: 96.2 | Pre: 79.3 Post: 98.6 | Pre: 84.8 Post: 92.8 | Pre: 68. Post: 73.7 |
| Knee Power (Ext) | Pre: 171.4 Post: 238.5 | Pre: 189.6 Post: 239.9 | Pre: 178.7 Post: 193.2 | Pre: 160.6 Post: 175.8 |
| Knee Power (Flex) | Pre: 84.1 Post: 131.0 | Pre: 110.9 Post: 150.3 | Pre: 104.6 Post: 112.3 | Pre: 81.3 Post: 94.2 |
III. Anaerobic and Aerobic Fitness
Anaerobic fitness relates to short bursts of intense activity, while Aerobic fitness (VO2 max) relates to sustained endurance.
| Metric | RT (Exercise Only) | RT+TM02 (Combined) | TM02 Only (LRS) | Placebo (Control) |
|---|---|---|---|---|
| Anaerobic Power (W/kg) | Pre: 7.6 Post: 8.2 | Pre: 8.2 Post: 8.9 | Pre: 8.7 Post: 9.1 | Pre: 9.1 Post: 9.4 |
| Anaerobic Capacity (W/kg) | Pre: 6.4 Post: 7.1 | Pre: 6.9 Post: 7.3 | Pre: 6.9 Post: 7.3 | Pre: 7.3 Post: 7.4 |
| VO2 Max (mL/kg/min) | Pre: 34.2 Post: 36.8 | Pre: 36.8 Post: 39.8 | Pre: 38.0 Post: 39.4 | Pre: 37.1 Post: 36.0 |
RT + TM02 vs. Placebo:
The combined group achieved the highest absolute performance values across nearly every strength and fitness metric by the end of the 8 weeks.
TM02 vs. RT:
While both groups saw improvements, the RT (Exercise only) group generally showed more significant gains in lower-body strength (knee torque) and anaerobic capacity compared to taking the TM02 alone.
RT vs. Placebo:
Resistance training alone significantly outperformed the placebo (control) group in muscular power and aerobic fitness.
The "Additive Benefit" Finding:
Although the RT + TM02 group showed excellent results, the researchers concluded that TM02 did not provide a statistically significant additional benefit beyond what was achieved by resistance training alone in this specific population of healthy young males.
Key Findings:
Muscular Strength (Peak Torque):
Significant gains
↗ in shoulder extension (+8.6 Nm) and knee flexion (+12.2 Nm).
Muscular Power:
Significant increase
↗ in average power for both shoulder and knee movements.
Aerobic Fitness (VO2 Max):
Increased ↗ from 36.8 to 39.8 mL/kg/min.
Anaerobic Performance:
Significant increases ↗ in both anaerobic power and capacity.
4. Post-Infectious Cough Relief
This study involved 34 patients who were treated with TM02® over a 6-week period.
Key Findings:
Leicester Cough Questionnaire:
Significant improvement in coughing symptoms (measured via the Leicester Cough Questionnaire - LCQ).
Validated Treatment:
The results formally cement the use of TM02® as an effective treatment for lingering coughs following an infection.
Clinically meaningful results:
The level of improvement exceeded the Minimal Clinically Important Difference (MCID) of 1.3, substantial enough for patients to notice a real difference in their daily comfort.
5. Allergic Rhinitis Relief
This was a larger study involving 108 patients who were treated with TM02® for 30 days.
Key Findings:
Significant improvement in nasal symptoms
(measured via the Total Nasal Symptom Score - TNSS)
Reduced allergic inflammation:
In patients who followed the protocol, symptom improvement was directly correlated with a decrease ↘ in plasma IL-5 levels.
Identified Mechanism:
The reduction in IL-5 suggests that the mushroom works by calming excessive allergic inflammation, which is the primary cause of allergic rhinitis discomfort.
TM02® Clinical Research Summary Table
| Health Focus | Key Results (Numbers & Arrows) | Simple Explanation |
|---|---|---|
| Asthma Support | Significant improvement in lung function (FEV1 increased ↗ by 0.3 L / Improved asthma control (reduced ↘ ACQ-7 scores by 0.8 points) / Reduced airway inflammation: •FeNO reduced ↘ by 43% •Lower ↘ eosinophil count and IgE levels | Opens up airways and significantly calms internal lung inflammation to help asthma patients breathe easier and feel better. |
| Lingering Cough | +4.3 points improvement ↗ in cough score (LCQ) / ↗ 3x higher ↗ than the minimum required for clinical success (MCID = 1.3) | Provides powerful relief for persistent, chronic coughs that often remain for weeks after a viral infection. |
| Nasal Allergies | ↗ Significant improvement ↗ in Nasal Symptom Score (TNSS) / Decrease ↘ in allergic proteins (IL-5) | Clears nasal congestion and sneezing by reducing the body’s overreaction to allergens like dust or pollen. |
| Cancer Recovery | Quality of Life (Global Health Status): Showed a significant within-patient improvement ↗ from a baseline of 68.13 to approximately 75.0 by the final visit. / Physical Functioning: Improved ↗ from a baseline of 81.0 to approximately 89.5 by the end of the study. / Observed a decreasing ↘ trend in fatigue scores compared to the placebo group. / Cellular Energy: Supplementation was noted to dramatically increase ↗ ATP production by improving mitochondrial function. | Helps survivors regain physical strength and reduces the extreme fatigue that follows intensive chemotherapy by boosting cellular energy (ATP). |
| Fitness & Strength | +8.6 Nm increase ↗ in shoulder strength / +12.2 Nm increase ↗ in knee strength / +3.0 mL/kg/min increase ↗ in endurance (VO2 Max) | Enhances muscle power and cardiovascular endurance, supporting active lifestyles even in healthy individuals. |
TM02® clinical research — at a glance
| Health Focus | Study design | Key results | In plain language |
|---|---|---|---|
| Asthma | Phase II · 17 adults · 90 days | FEV1 +20.1% · FeNO –43% · Eosinophils –48.7% · IgE –22.1% | Opens airways and calms lung inflammation |
| Cancer recovery | RCT placebo-controlled · 52 patients · 6 months | GHS 68.1→75.0 · Physical functioning 81.0→89.5 · ↑ ATP · ↓ Fatigue | Reduces post-chemo fatigue, boosts cellular energy |
| Fitness | Double-blind · 40 males · 8 weeks | Shoulder ext. +8.6 Nm · Knee flex. +12.2 Nm · VO2 max 36.8→39.8 mL/kg/min | Enhances muscle power and endurance |
| Cough | Open-label · 34 patients · 6 weeks | LCQ 13.6→17.9 (+4.3 pts) · 3× MCID threshold of 1.3 | Clinically validated post-infection cough relief |
| Allergic rhinitis | Observational · 108 patients · 30 days | TNSS improved significantly · Plasma IL-5 decreased | Clears nasal congestion by targeting root-cause inflammation |
Production Technology
LiGNO Biotech TM02®
Proprietary solid-state fermentation (controlled & consistent)
Other TMM Varieties
Variable cultivation methods
Strain
LiGNO Biotech TM02®
Proprietary, MOA-registered
Other TMM Varieties
Non-proprietary, often undefined
Cultivation
LiGNO Biotech TM02®
Food-based substrate
Other TMM Varieties
Sawdust, soil, or liquid media
Standardisation
LiGNO Biotech TM02®
Validated Bioactive Profile
Other TMM Varieties
Limited or generic evidence
Scientific Validation
LiGNO Biotech TM02®
Backed by research and safety data
Other TMM Varieties
β-Glucan / Polysaccharide Only
Certification
LiGNO Biotech TM02®
BISO22000, GMP, HACCP, Halal, organic, Kosher
Other TMM Varieties
Certification varies by supplier
Production Technology
LiGNO Biotech TM02®
Proprietary solid-state fermentation (controlled & consistent)
Other TMM Varieties
Variable cultivation methods
Strain
Proprietary, MOA-registered
Non-proprietary, often undefined
Cultivation
Food-based substrate
Sawdust, soil, or liquid media
Standardisation
Validated Bioactive Profile
Limited or generic evidence
Scientific Validation
Backed by research and safety data
β-Glucan / Polysaccharide Only
Certification
BISO22000, GMP, HACCP, Halal, organic, Kosher
Certification varies by supplier
TM02®
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
TM02®
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Why LiGNO TM02® Stands Apart
TM02® VS Other Tiger Milk Mushroom Sources
LiGNO TM02®
Production Technology
Registered variety under the Ministry of Agriculture
Safety Data
Clinically proven, backed by human safety data
Facility & Environment
Cultivated in certified, controlled lab environments, free from pesticides, heavy metals, and contaminants
Cultivation Method
Patented cultivation on food-based substrates
Scientific Validation
Supported by scientific research and proven efficacy
Other TMM Varieties
Registration
Unregistered varieties with no official recognition
Safety Data
Unclear source of safety data available for human use
Facility & Environment
Grown in uncontrolled environments, prone to contamination
Cultivation Method
Cultivated with soil or chemical substrates
Scientific Validation
Lacks scientific validation
Feature
LiGNO TM02®
Other TMM Varieties
Registration
Registered variety under the Ministry of Agriculture
Unregistered varieties with no official recognition
Safety Data
Clinically proven, backed by human safety data
Unclear source of safety data available for human use
Facility & Environment
Cultivated in certified, controlled lab environments, free from pesticides, heavy metals, and contaminants
Grown in uncontrolled environments, prone to contamination
Cultivation Method
Patented cultivation on food-based substrates
Cultivated with soil or chemical substrates
Scientific Validation
Supported by scientific research and proven efficacy
Lacks scientific validation
World’s First,
Global Pioneer in
Tiger Milk Mushroom Cultivation
From Malaysia’s rainforests, LiGNO Biotech pioneered the world’s first cultivation of the Tiger Milk Mushroom, transforming a centuries-old tradition into a clinically validated wellness solution.
LiGNO®
Functional Mushroom Ingredients
The Tiger Milk Mushroom is Malaysia’s national treasure, revered for over 400 years in traditional medicine. Long celebrated for its remarkable properties, it supports lung and respiratory health, strengthens immunity, eases joint discomfort, and promotes overall vitality.
Resilience. Recovery. Renewal.
LiGNO TM02®
Tiger Milk Mushroom
Scientific Name
Lignosus rhinocerus
Common Name
Tiger Milk Mushroom, Cendawan Susu Harimau, 虎乳芝
About LiGNO TM02®
LiGNO TM02® Tiger Milk Mushroom is a special selected strain of Lignosus rhinocerus, developed through proprietary cultivation technology to ensure consistent quality, verified strain identity, and reliable bioactive composition.
It is also recognized as one of the most researched Tiger Milk Mushroom cultivars, supported by a growing body of preclinical and clinical studies evaluating its immunomodulatory, antiinflammatory and respiratory health-related properties.
Produced under strict quality standards, TM02® is designed for nutraceutical, functional food, and wellness applications, providing a scalable and scientifically validated source of this rare medicinal mushroom.
Key Health Benefits
LiGNO TM02® Bioactivities
Scientifically Validated Bioactivities
Anti-inflammatory
Immunomodulating
Bronchodilating
Anti-asthmatic Activity
Anti-proliferative
Anti-viral
Improves Insulin Sensitivity
Antioxidant
Anti-glycation
Enhances ATP And Energy Production
Neurotrophic (Supports Nerve Growth)
Product Specifications
≥15% Glycoprotein
≥30% Total Polysaccharides
≥15% Beta Glucan
Applications
LiGNO TM02® is a versatile ingredient, perfect for a wide range of product categories, including:
Nutraceuticals
Functional Food & Beverage
Dietary Supplements
Skincare
Products
Pet Health
Products
Applications
LiGNO TM02® is a versatile ingredient, perfect for a wide range of product categories, including:
Nutraceuticals
Functional Food & Beverage
Dietary Supplements
Skincare Products
Pet Health Products
TM02®
Portfolio
LiGNO TM02® Skincare Extract
A standardized cold-water extract formulated for skincare applications.
Soothe irritated skin caused by allergies
Calm eczema-prone or sensitive skin
Promote overall skin wellness and resilience
Study 1 of 6 . PHASE II . RESPIRATORY
Respiratory Health
A Phase II clinical study investigated TM02® as a complementary support for individuals with uncontrolled asthma.
17 adults
with uncontrolled asthma
90 Days
Duration
Improvement in lung function
+0.3L
Significant improvement in lung function (FEV1 increased by 0.3 L)
aSTHMA CONTROL
-0.8
Improved asthma control (reduced ACQ-7 scores by 0.8 points)
AIRWAY INFLAMMATION
-43%
FeNO reduced by 43%, with lower eosinophil count and IgE levels.
TM02® may support respiratory health by improving breathing function and reducing inflammation.
TM02®
Clinically Researched
+20.1%
Lung function (FEV1)
-43%
Airway inflammation (FeNO)
–48.7%
Blood eosinophils
–22.1%
Serum IgE antibodies
Lung function — FEV1
+0.3 L (20.1%)
Airway inflammation — FeNO
–21.2 ppb (43%)
Asthma symptoms — ACQ-7
–0.8 units
Blood eosinophils
–48.7%
Serum IgE
–22.1%
Study 2 of 6 · Randomized, Double-Blind, Placebo-Controlled Clinical
Post-Infectious Cough Relief
Focus Area: Long-COVID Chronic Cough Relief
34 Patients
with Post-acute Covid-19 sydrome
6 Weeks
Duration
Quality Of life
Improved
LCQ SCORE
4.3 pts
*Exceeded the Minimal Clinically Important Difference (MCID) of 1.3
Clinical evidence supports TM02® as an effective adjunct that significantly improves cough-related quality of life in individuals with persistent post-viral respiratory symptoms.
TM02®
Clinically Researched
+20.1%
Lung function (FEV1)
-43%
Airway inflammation (FeNO)
–48.7%
Blood eosinophils
–22.1%
Serum IgE antibodies
Lung function — FEV1
+0.3 L (20.1%)
Airway inflammation — FeNO
–21.2 ppb (43%)
Asthma symptoms — ACQ-7
–0.8 units
Blood eosinophils
–48.7%
Serum IgE
–22.1%
Study 3 of 6 · Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Allergic Rhinitis Relief
Focus Area: Long-COVID Chronic Cough Relief
108 Patients
with allergic rhinthis
30 Days
Duration
Nasal Symptoms
Improved
IL-5 Levels
Decreased
In adhering patients, symptom improvement was directly correlated with a decrease in plasma IL-5 levels.
TM02® reduces excessive allergic inflammation, representing a potential mechanism of action in alleviating allergic rhinitis.
TM02®
Clinically Researched
+20.1%
Lung function (FEV1)
-43%
Airway inflammation (FeNO)
–48.7%
Blood eosinophils
–22.1%
Serum IgE antibodies
Lung function — FEV1
+0.3 L (20.1%)
Airway inflammation — FeNO
–21.2 ppb (43%)
Asthma symptoms — ACQ-7
–0.8 units
Blood eosinophils
–48.7%
Serum IgE
–22.1%
Study 4 of 6 · Randomized, Double-Blind, Placebo-Controlled Trial
Immune Recovery
Focus Area: Post-Chemotherapy Recovery, Fatigue Management, and Quality of Life Enhancement
52 Immune-Challenged Patients
with localised breast cancer
6 Months
Duration
Physical & Emotional Vitality
Improved
Fatigue Alleviation
Reduced
TM02® reduces excessive allergic inflammation, representing a potential mechanism of action in alleviating allergic rhinitis.
TM02®
Clinically Researched
+20.1%
Lung function (FEV1)
-43%
Airway inflammation (FeNO)
–48.7%
Blood eosinophils
–22.1%
Serum IgE antibodies
Lung function — FEV1
+0.3 L (20.1%)
Airway inflammation — FeNO
–21.2 ppb (43%)
Asthma symptoms — ACQ-7
–0.8 units
Blood eosinophils
–48.7%
Serum IgE
–22.1%
Study 5 of 6 · Randomized, Double-Blind, Placebo-Controlled
Physical Performance
40
healthy young males
8 Weeks
Duration
MUSCLE SUPPORT
Improved
TM02® serves as an excellent daily wellness staple that supports upper-body muscular performance and maintains a flawless safety profile for human consumption.
TM02®
Clinically Researched
+20.1%
Lung function (FEV1)
-43%
Airway inflammation (FeNO)
–48.7%
Blood eosinophils
–22.1%
Serum IgE antibodies
Lung function — FEV1
+0.3 L (20.1%)
Airway inflammation — FeNO
–21.2 ppb (43%)
Asthma symptoms — ACQ-7
–0.8 units
Blood eosinophils
–48.7%
Serum IgE
–22.1%
Study 6 of 6 · Prospective, Open-Label, Split-Site Pilot Study
Natural, Steroid-Free Eczema Relief
Focus Area: Atopic dermatitis
20 Patients
with mild-to-moderate atopic dermatitis
6 Weeks
Duration
VS. STEROID
Comparable
SKIN HEALTH
Improved
LONG TERM USE
Safe
Day 0 — Baseline
Week 6 — After Treatment
Topical TM02-Ex provides a safe, effective, and natural alternative that achieves significant clinical improvement in eczema symptoms within six weeks.
TM02®
Clinically Researched
+20.1%
Lung function (FEV1)
-43%
Airway inflammation (FeNO)
–48.7%
Blood eosinophils
–22.1%
Serum IgE antibodies
Lung function — FEV1
+0.3 L (20.1%)
Airway inflammation — FeNO
–21.2 ppb (43%)
Asthma symptoms — ACQ-7
–0.8 units
Blood eosinophils
–48.7%
Serum IgE
–22.1%
Clinically Proven: The TM02® Portfolio
Six human clinical studies spanning respiratory health, oncology recovery, physical performance, cough relief, and allergic rhinitis.
SUMMARY OF CLINICAL TRIAL OF TIGER MILK MUSHROOM
1. Respiratory Health (Asthma Study)
A Phase II clinical study investigated TM02® as a complementary support for individuals with uncontrolled asthma.
Participants
17 adults with asthma
Duration
90 days
Dosage
600 mg → 1,200 mg daily
| Parameter | Direction | Number/Percentage | Description |
|---|---|---|---|
| Lung Function (FEV1) | Increase | +0.3 Liters (20.1%) | Demonstrates improved airway patency and significantly better lung capacity. |
| Airway Inflammation (FeNO) | Decrease | -21.2 ppb (43%) | Indicates a major reduction in allergic airway inflammation, which is a key driver of asthma symptoms. |
| Asthma Symptoms (ACQ-7) | Decrease | -0.8 units | A reduction in the "Asthma Control Questionnaire" score, meaning patients experienced significantly fewer symptoms and better quality of life. |
| Blood Eosinophils | Decrease | 48.7% | A drop in the specific white blood cells responsible for causing lung tissue damage and asthma attacks. |
| Serum IgE | Decrease | 22.1% | Lowered levels of Immunoglobulin E (IgE) antibodies, showing a reduction in the body's overactive allergic response |
Key Findings:
Significant improvement in lung function:
(FEV1 increased
↗ by 0.3 L)
Improved asthma control:
(reduced
↘ ACQ-7 scores by 0.8 points)
Reduced airway inflammation:
• FeNO reduced ↘ by 43%
• Lower ↘ eosinophil count and IgE levels
Conclusion:
TM02® may support respiratory health by improving breathing function and reducing inflammation.
2.
Cancer Recovery (Breast Cancer Study)
A randomized, double-blind, placebo-controlled trial evaluated TM02® in patients recovering from breast cancer treatment.
Participants
52 patients
Duration
6 months
Dosage
1,040 mg daily
| Parameter | Direction | Key Detail |
|---|---|---|
| Global Health Status (GHS) | Increase | There was a significant within-patient improvement in overall health and quality of life scores across the 6-month study. |
| Physical Functioning | Increase | A positive trend was observed in patients' ability to perform daily physical activities compared to the placebo group. |
| ATP (Energy) Production | Increase | Supplementation is linked to dramatically increased ATP production by improving mitochondrial function. |
| Fatigue Scores | Decrease | There was a noticeable decreasing trend in fatigue, with survivors in the TM02® group reporting lower tiredness levels than those on the placebo. |
Key Findings:
Quality of Life (Global Health Status):
Showed a significant within-patient improvement
↗ from a baseline of 68.13 to approximately 75.0 by the final visit.
Physical Functioning:
Improved
↗ from a baseline of 81.0 to approximately 89.5 by the end of the study.
Fatigue Score:
Observed a decreasing trend in fatigue scores compared to the placebo group.
Cellular Energy:
Supplementation was noted to dramatically increase ↗ ATP production by improving mitochondrial function.
Conclusion: TM02® may help improve overall well-being and reduce fatigue in post-treatment recovery.
3. Physical Fitness (Resistance Training Study)
A double-blind study evaluated TM02® in combination with resistance training.
Participants
40 healthy young males
Duration
8 weeks
Dosage
500 mg daily
I. Muscular Strength (Peak Torque at 60°/s in Nm)
These figures represent the maximum force generated by the muscles. Higher numbers indicate greater strength.
| Metric | RT (Exercise Only) | RT+TM02 (Combined) | TM02 Only (LRS) | Placebo (Control) |
|---|---|---|---|---|
| Shoulder Extension | Pre: 56.7 Post: 63.2 | Pre: 63.6 Post: 72.2 | Pre: 52.0 Post: 64.1 | Pre: 58.2 Post: 52.9 |
| Shoulder Flexion | Pre: 53.6 Post: 59.4 | Pre: 59.0 Post: 61.1 | Pre: 56.8 Post: 60.0 | Pre: 47.7 Post: 49.0 |
| Knee Extension | Pre: 143.3 Post: 166.1 | Pre: 173.4 Post: 187.0 | Pre: 149.5 Post: 152.5 | Pre: 138.0 Post: 141.7 |
| Knee Flexion | Pre: 62.2 Post: 75.0 | Pre: 77.8 Post: 90.0 | Pre: 63.8 Post: 72.6 | Pre: 64.1 Post: 69.9 |
II. Muscular Power (Average Power at 300°/s in Watts)
This measures the ability to exert force quickly. Higher numbers indicate more explosive power.
| Metric | RT (Exercise Only) | RT+TM02 (Combined) | TM02 Only (LRS) | Placebo (Control) |
|---|---|---|---|---|
| Shoulder Power (Ext) | Pre: 63.0 Post: 96.9 | Pre: 84.6 Post: 118.9 | Pre: 81.4 Post: 95.1 | Pre: 61.9 Post: 64.3 |
| Shoulder Power (Flex) | Pre: 75.7 Post: 96.2 | Pre: 79.3 Post: 98.6 | Pre: 84.8 Post: 92.8 | Pre: 68. Post: 73.7 |
| Knee Power (Ext) | Pre: 171.4 Post: 238.5 | Pre: 189.6 Post: 239.9 | Pre: 178.7 Post: 193.2 | Pre: 160.6 Post: 175.8 |
| Knee Power (Flex) | Pre: 84.1 Post: 131.0 | Pre: 110.9 Post: 150.3 | Pre: 104.6 Post: 112.3 | Pre: 81.3 Post: 94.2 |
III. Anaerobic and Aerobic Fitness
Anaerobic fitness relates to short bursts of intense activity, while Aerobic fitness (VO2 max) relates to sustained endurance.
| Metric | RT (Exercise Only) | RT+TM02 (Combined) | TM02 Only (LRS) | Placebo (Control) |
|---|---|---|---|---|
| Anaerobic Power (W/kg) | Pre: 7.6 Post: 8.2 | Pre: 8.2 Post: 8.9 | Pre: 8.7 Post: 9.1 | Pre: 9.1 Post: 9.4 |
| Anaerobic Capacity (W/kg) | Pre: 6.4 Post: 7.1 | Pre: 6.9 Post: 7.3 | Pre: 6.9 Post: 7.3 | Pre: 7.3 Post: 7.4 |
| VO2 Max (mL/kg/min) | Pre: 34.2 Post: 36.8 | Pre: 36.8 Post: 39.8 | Pre: 38.0 Post: 39.4 | Pre: 37.1 Post: 36.0 |
RT + TM02 vs. Placebo:
The combined group achieved the highest absolute performance values across nearly every strength and fitness metric by the end of the 8 weeks.
TM02 vs. RT:
While both groups saw improvements, the RT (Exercise only) group generally showed more significant gains in lower-body strength (knee torque) and anaerobic capacity compared to taking the TM02 alone.
RT vs. Placebo:
Resistance training alone significantly outperformed the placebo (control) group in muscular power and aerobic fitness.
The "Additive Benefit" Finding:
Although the RT + TM02 group showed excellent results, the researchers concluded that TM02 did not provide a statistically significant additional benefit beyond what was achieved by resistance training alone in this specific population of healthy young males.
Key Findings:
Muscular Strength (Peak Torque):
Significant gains
↗ in shoulder extension (+8.6 Nm) and knee flexion (+12.2 Nm).
Muscular Power:
Significant increase
↗ in average power for both shoulder and knee movements.
Aerobic Fitness (VO2 Max):
Increased ↗ from 36.8 to 39.8 mL/kg/min.
Anaerobic Performance:
Significant increases ↗ in both anaerobic power and capacity.
4. Post-Infectious Cough Relief
This study involved 34 patients who were treated with TM02® over a 6-week period.
Key Findings:
Leicester Cough Questionnaire:
Significant improvement in coughing symptoms (measured via the Leicester Cough Questionnaire - LCQ).
Validated Treatment:
The results formally cement the use of TM02® as an effective treatment for lingering coughs following an infection.
Clinically meaningful results:
The level of improvement exceeded the Minimal Clinically Important Difference (MCID) of 1.3, substantial enough for patients to notice a real difference in their daily comfort.
5. Allergic Rhinitis Relief
This was a larger study involving 108 patients who were treated with TM02® for 30 days.
Key Findings:
Significant improvement in nasal symptoms
(measured via the Total Nasal Symptom Score - TNSS)
Reduced allergic inflammation:
In patients who followed the protocol, symptom improvement was directly correlated with a decrease ↘ in plasma IL-5 levels.
Identified Mechanism:
The reduction in IL-5 suggests that the mushroom works by calming excessive allergic inflammation, which is the primary cause of allergic rhinitis discomfort.
TM02® Clinical Research Summary Table
| Health Focus | Key Results (Numbers & Arrows) | Simple Explanation |
|---|---|---|
| Asthma Support | Significant improvement in lung function (FEV1 increased ↗ by 0.3 L / Improved asthma control (reduced ↘ ACQ-7 scores by 0.8 points) / Reduced airway inflammation: •FeNO reduced ↘ by 43% •Lower ↘ eosinophil count and IgE levels | Opens up airways and significantly calms internal lung inflammation to help asthma patients breathe easier and feel better. |
| Lingering Cough | +4.3 points improvement ↗ in cough score (LCQ) / ↗ 3x higher ↗ than the minimum required for clinical success (MCID = 1.3) | Provides powerful relief for persistent, chronic coughs that often remain for weeks after a viral infection. |
| Nasal Allergies | ↗ Significant improvement ↗ in Nasal Symptom Score (TNSS) / Decrease ↘ in allergic proteins (IL-5) | Clears nasal congestion and sneezing by reducing the body’s overreaction to allergens like dust or pollen. |
| Cancer Recovery | Quality of Life (Global Health Status): Showed a significant within-patient improvement ↗ from a baseline of 68.13 to approximately 75.0 by the final visit. / Physical Functioning: Improved ↗ from a baseline of 81.0 to approximately 89.5 by the end of the study. / Observed a decreasing ↘ trend in fatigue scores compared to the placebo group. / Cellular Energy: Supplementation was noted to dramatically increase ↗ ATP production by improving mitochondrial function. | Helps survivors regain physical strength and reduces the extreme fatigue that follows intensive chemotherapy by boosting cellular energy (ATP). |
| Fitness & Strength | +8.6 Nm increase ↗ in shoulder strength / +12.2 Nm increase ↗ in knee strength / +3.0 mL/kg/min increase ↗ in endurance (VO2 Max) | Enhances muscle power and cardiovascular endurance, supporting active lifestyles even in healthy individuals. |
TM02® clinical research — at a glance
| Health Focus | Study design | Key results | In plain language |
|---|---|---|---|
| Asthma | Phase II · 17 adults · 90 days | FEV1 +20.1% · FeNO –43% · Eosinophils –48.7% · IgE –22.1% | Opens airways and calms lung inflammation |
| Cancer recovery | RCT placebo-controlled · 52 patients · 6 months | GHS 68.1→75.0 · Physical functioning 81.0→89.5 · ↑ ATP · ↓ Fatigue | Reduces post-chemo fatigue, boosts cellular energy |
| Fitness | Double-blind · 40 males · 8 weeks | Shoulder ext. +8.6 Nm · Knee flex. +12.2 Nm · VO2 max 36.8→39.8 mL/kg/min | Enhances muscle power and endurance |
| Cough | Open-label · 34 patients · 6 weeks | LCQ 13.6→17.9 (+4.3 pts) · 3× MCID threshold of 1.3 | Clinically validated post-infection cough relief |
| Allergic rhinitis | Observational · 108 patients · 30 days | TNSS improved significantly · Plasma IL-5 decreased | Clears nasal congestion by targeting root-cause inflammation |
International Certifications
Manufactured under GMP, HACCP, ISO 22000, Halal, Kosher and myOrganic certified facilities.
Standardised Bioactive Profile
Every batch is validated for consistent bioactive composition to support reliable product performance.
Exclusive TM02® cultivar registered under the Malaysian Department of Agriculture (MOA), ensuring identity, consistency and authenticity.
The LiGNO TM02® Difference
Setting the Global Standard in Tiger Milk Mushroom Innovation
What Makes LiGNO TM02® Different
LiGNO TM02® Advantage
Proprietary Cultivar
Exclusive TM02® cultivar registered under the Malaysian Department of Agriculture (MOA), ensuring identity, consistency and authenticity.
Advanced Production Technology
Produced using proprietary solid-state fermentation for batch-to-batch consistency and scalable quality.
Food-Based Cultivation
Cultivated on a carefully selected food-grade substrate to support clean, safe, controlled production.
Standardised Bioactive Profile
Every batch is validated for consistent bioactive composition to support reliable product performance.
Strong Scientific Foundation
Supported by 20+ years of research and 60+ scientific publications, including preclinical and clinical studies.
Comprehensive Safety Validation
Backed by full toxicology studies and human clinical safety evaluations.
International Certifications
Manufactured under GMP, HACCP, ISO 22000, Halal, Kosher and myOrganic certified facilities.
Production Technology
LiGNO Biotech TM02®
Proprietary solid-state fermentation (controlled & consistent)
Other TMM Varieties
Variable cultivation methods
Strain
LiGNO Biotech TM02®
Proprietary, MOA-registered
Other TMM Varieties
Non-proprietary, often undefined
Cultivation
LiGNO Biotech TM02®
Food-based substrate
Other TMM Varieties
Sawdust, soil, or liquid media
Standardisation
LiGNO Biotech TM02®
Validated Bioactive Profile
Other TMM Varieties
Limited or generic evidence
Scientific Validation
LiGNO Biotech TM02®
Backed by research and safety data
Other TMM Varieties
β-Glucan / Polysaccharide Only
Certification
LiGNO Biotech TM02®
BISO22000, GMP, HACCP, Halal, organic, Kosher
Other TMM Varieties
Certification varies by supplier
Production Technology
LiGNO Biotech TM02®
Proprietary solid-state fermentation (controlled & consistent)
Other TMM Varieties
Variable cultivation methods
Strain
Proprietary, MOA-registered
Non-proprietary, often undefined
Cultivation
Food-based substrate
Sawdust, soil, or liquid media
Standardisation
Validated Bioactive Profile
Limited or generic evidence
Scientific Validation
Backed by research and safety data
β-Glucan / Polysaccharide Only
Certification
BISO22000, GMP, HACCP, Halal, organic, Kosher
Certification varies by supplier
TM02®
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
TM02®
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Production Technology
Proprietary solid-state fermentation (controlled & consistent)
Why LiGNO TM02® Stands Apart
TM02® VS Other Tiger Milk Mushroom Sources
LiGNO TM02®
Production Technology
Registered variety under the Ministry of Agriculture
Safety Data
Clinically proven, backed by human safety data
Facility & Environment
Cultivated in certified, controlled lab environments, free from pesticides, heavy metals, and contaminants
Cultivation Method
Patented cultivation on food-based substrates
Scientific Validation
Supported by scientific research and proven efficacy
Other TMM Varieties
Registration
Unregistered varieties with no official recognition
Safety Data
Unclear source of safety data available for human use
Facility & Environment
Grown in uncontrolled environments, prone to contamination
Cultivation Method
Cultivated with soil or chemical substrates
Scientific Validation
Lacks scientific validation
Feature
LiGNO TM02®
Other TMM Varieties
Registration
Registered variety under the Ministry of Agriculture
Unregistered varieties with no official recognition
Safety Data
Clinically proven, backed by human safety data
Unclear source of safety data available for human use
Facility & Environment
Cultivated in certified, controlled lab environments, free from pesticides, heavy metals, and contaminants
Grown in uncontrolled environments, prone to contamination
Cultivation Method
Patented cultivation on food-based substrates
Cultivated with soil or chemical substrates
Scientific Validation
Supported by scientific research and proven efficacy
Lacks scientific validation
Ready to incorporate TM02® into your formulation?
Backed by 60+ peer-reviewed publications · GMP · Halal · HACCP · myOrganic · ISO 22000 · Kosher
